EVOKE PHARMA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-11-13: Form 8-K; Period of report 2018-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-08-16: Form 8-K; Period of report 2018-08-16; Description 8.01 Other Events.
- 2018-08-09: Form 8-K; Period of report 2018-08-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-06-04: Form 8-K; Period of report 2018-06-04; Description 8.01 Other Events.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-11-13 | 8-K | 2018-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2018, Evoke Pharma, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2018. | evok-8k_20180930.htm |
| 2018-08-16 | 8-K | 2018-08-16 | 8.01 Other Events | evok-8k_20180816.htm | |
| 2018-08-09 | 8-K | 2018-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2018, Evoke Pharma, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2018. | evok-8k_20180630.htm |
| 2018-06-04 | 8-K | 2018-06-04 | 8.01 Other Events | evok-8k_20180601.htm | |
| 2018-05-14 | 8-K | 2018-05-14 | 2.02 Results of Operations and Financial Condition | 2.02 On May 14, 2018, Evoke Pharma, Inc. issued a press release announcing its financial results for the first quarter of 2018. | evok-8k_20180514.htm |
| 2018-05-10 | 8-K | 2018-05-09 | 8.01 Other Events | 8.01 On May 10, 2018, Evoke Pharma, Inc. (the “Company”) announced that the Mexican Institute of Industrial Property has issued a Notice that it intends to grant Mexican Patent Application MX/a/2014/002125 for Gimoti™, covering uses of metoclopramide for intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis specifically for women. | evok-8k_20180509.htm |
| 2018-04-30 | 8-K | 2018-04-30 | 8.01 Other Events | 8.01 On April 30, 2018, Evoke Pharma, Inc. (the “Company”) announced that the European Patent Office has issued a Decision to Grant European Union (EU) patent no. | evok-8k_20180430.htm |
| 2018-04-27 | 8-K | 2018-04-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 Evoke Pharma, Inc. (the “Company”) held its annual meeting of stockholders on April 26, 2018 (the “Annual Meeting”). 5.07 The Annual Meeting was held on April 26, 2018. | evok-8k_20180426.htm |
| 2018-04-06 | 8-K/A | 2018-03-29 | 1.01 Entry into a Material Definitive Agreement | evok-8ka_20180329.htm | |
| 2018-04-04 | 8-K | 2018-03-29 | 1.01 Entry into a Material Definitive Agreement | evok-8k_20180329.htm | |
| 2018-03-26 | 8-K | 2018-03-21 | 8.01 Other Events | 8.01 On March 21, 2018, Evoke Pharma, Inc. (“Evoke” or the “Company”) entered into an Amendment to Asset Purchase Agreement (the “Amendment”) with Mallinckrodt ARD Inc. (formerly known as Questcor Pharmaceuticals, Inc.) (“Mallinckrodt”) to amend certain terms of the Asset Purchase Agreement, dated as of June 1, 2007 (as subsequently amended, the “Asset Purchase Agreement”). | evok-8k_20180321.htm |
| 2018-03-23 | 8-K | 2018-03-22 | 1.01 Entry into a Material Definitive Agreement | evok-8k_20180322.htm | |
| 2018-03-07 | 8-K | 2018-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2018, Evoke Pharma, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2017. | evok-8k_20180307.htm |
| 2018-03-05 | 8-K | 2018-03-05 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Additionally, the Company announced it is now able to extend its cash runway into October 2018. 8.01 On March 5, 2018, Evoke Pharma, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (FDA) granted the Company’s request for a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of approximately $2.4 million for its 505(b)(2) New Drug Application (NDA) for Gimoti™, the Company’s nasal delivery of metoclopramide for the treatment of symptoms associated with gastroparesis in women. | evok-8k_20180305.htm |
| 2018-02-15 | 8-K | 2018-02-15 | 8.01 Other Events | 8.01 On February 15, 2018, Evoke Pharma, Inc. (the “Company”) announced additional findings from its comparative exposure pharmacokinetic (PK) trial for Gimoti™, the Company’s novel nasal spray delivery of metoclopramide for the treatment of symptoms associated with gastroparesis. | evok-8k_20180215.htm |